Healthcare / Medical DevicesASX
$1.10
-0.06 (-5.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-8.1M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$763M
P/E
110.5x
↑EV/EBITDA
72.3x
↑ROE
15.9%
↑Gross Margin
95.9%
↑Debt/Equity
0.21
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+45.3%
FCF CAGR
—
FCF margin
-8.5%
FCF / Net income
-0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $127.2M · net income $13.2M · FCF $-10.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $127.2M | $127.2M | $103.2M | $65.2M | $41.4M |
| Net Income | $13.2M | $13.2M | $5.3M | $-4.9M | $-1.2M |
| EBITDA | $10.5M | $10.5M | $4.0M | $-2.7M | $753458.00 |
| EPS | 0.02 | 0.02 | 0.01 | -0.01 | -0.00 |
| Gross Margin | 95.9% | 95.9% | 94.7% | 93.2% | 94.7% |
| Operating Margin | 3.5% | 3.5% | 1.1% | -9.5% | -0.6% |
| Net Margin | 10.4% | 10.4% | 5.1% | -7.5% | -2.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.21 | 0.21 | 0.21 | 0.25 | 0.62 |
| Current Ratio | 3.04 | 3.04 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.8M | $-10.8M | $786000.00 | $-8.1M | $-2.5M |
| Returns | |||||
| ROE | 15.9% | 15.9% | 7.3% | -7.5% | -6.7% |
| Valuation | |||||
| P/E | 110.50 | 110.50 | 314.67 | — | — |
| EV/EBITDA | 72.35 | 72.35 | 401.52 | — | 1374.80 |
| P/B | 9.28 | 9.28 | 22.95 | 14.66 | 58.20 |
| Growth & Yield | |||||
| Revenue Growth | 23.3% | 23.3% | 58.2% | 57.4% | — |
| EPS Growth | 152.0% | 152.0% | 204.2% | -300.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
73.1%
EPS terminal req.
$0.10
Spread vs growth
78.9%
5Y implied EPS CAGR
44.4%
EPS terminal req.
$0.12
Spread vs growth
107.6%
10Y implied EPS CAGR
26.0%
EPS terminal req.
$0.19
Spread vs growth
126.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.5%
Start / end P/E
178.7x → 58.5x
EPS bridge
0.01 → 0.02
Residual
-102.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.